-
Cell Stem Cell: How smoking exacerbates the infection of the new coronavirus in the lungs
Time of Update: 2020-11-28
November 18, 2020 // -- In a recent study, researchers at the University of California, Los Angeles, used models of respiratory tissue produced by human stem cells to determine how smoking exacerbates SARS-CoV-2 infections in respiratory tissue.
-
STM: The intrinsic mechanism of immune rejection of stem cell transplantation
Time of Update: 2020-11-28
November 19, 2020 // -- In the treatment of leukemia, stem cell transplants after chemotherapy and radiotherapy often cause severe adverse inflammatory reactions, especially in the skin or intestines, as these so-called "barrier" organs are more susceptible.
-
Cell Metabolism: Key metabolic path paths regulate T-cell activity
Time of Update: 2020-11-28
understanding how metabolic signaling regulates the heterogeneity or function of Treg cells may help scientists develop more specific drugs to target these pathways to help treat diseases.
-
JCI interpretation! In-depth understanding of the pathogenesis of rare diabetes may help clarify the mysteries of insulin production in the body!
Time of Update: 2020-11-28
18, 2020 // -- In a recent study published in the international journal Journal of Clinical Investigation, scientists from the University of Exeter and others revealed the molecular mechanisms of insu
-
Primary bile bile bileitis (PBC) breakthrough drug! PPAR astrist seladelpar Phase 3 clinically demonstrated strong results!
Time of Update: 2020-11-27
"PBC" (Photo: Genfit.com) ENHANCE is a randomized, double-blind, placebo-controlled global study that included 265 PBC patients who did not respond well to UDCA (UDCA) in bears (after at least 12 months of treatment, serum alkaline phosphatase levels (ALP) ≥1.67 times normal upper limit (ULN) or poor resistance to CUDA.
-
Cell sub-journal interpretation! Scientists dig deep into antibody spectrum to find a cure for SARS-CoV-2!
Time of Update: 2020-11-27
When the relevant research began, the public database of antigen-specific SARS-CoV-2 antibody sequences was still quite limited, and as the researchers point out, this study represents only one starting point and a useful reference library for virus-related sequences, the relationship between which remains to be further studied by later scientists on the nature of the body's immune response to the virus.
-
Interstuming stem cell therapy! Novart signs license agreement with Mesoblast: Remestemcel-L to treat acute respiratory distress (ARDS)!
Time of Update: 2020-11-27
Nov 22, 2020 // -- Novartis recently announced that it has signed an exclusive global license and cooperation agreement with Mesoblast to develop and commercialize the isomer-filled stem cell (MSC) therapy Ryoncil(remestemcel-L) for the treatment of acute respiratory distress syndrome (ARDS), including ARDS associated with the new coronavirus pneumonia (COVID-19).
-
Nature: New research suggests that in-tumor B cells may be an important aspect of developing cancer immunotherapy
Time of Update: 2020-11-27
" Wieland, Ahmed, and their colleagues decided to focus on hpicular influenza virus (HPV)-positive head and neck cancer because the virus provides a determined set of tumor-related antigens that make it easier to study tumor-specific B cells in patients.
-
The Lancet: The results of phase II clinical trials of the COVID-19 vaccine at Oxford University were positive
Time of Update: 2020-11-27
() Source: Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and challenges immune response Original source: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine a prime-regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial, The Lancet (2020).
-
New Crown Outbreak: 57.23 million! Lilly is granted the FDA's second Emergency Use Authorization (EUA): Olumiant and Redsiway treat hospitalized patients!
Time of Update: 2020-11-27
recently, Eli Lilly and partner Incyte jointly announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for distribution and emergency use of Olumiant (baricitinib, Baritini) in partnership with Veklury (Baricitini) remdesivir, Redsivir), for hospitalized adults and pediatric patients with suspected or laboratory-confirmed new coronavirus pneumonia (COVID-19), oxygen rehydration/invasive mechanical aeration/in vitro membrane pulmonary oxygenation (ECMO), age ≥2 years of age.
-
Europe's first recombined influenza vaccine! Sanofi's 4-price vaccine Supertek has been approved by the European Union to prevent influenza ≥ 18-year-olds!
Time of Update: 2020-11-27
Phase 3 efficacy trial showed that Supemtek's ability to protect against influenza improved compared to the standard dose of the egg-based teteal flu vaccine, reducing the risk of influenza in adults aged 50 and over by an additional 30 percent.
-
The world's first long-acting C5 inhibitor! EU approves Ultomiris 100mg/mL high concentration preparation: 60% reduction in infusion time!
Time of Update: 2020-11-27
November 21, 2020 // -- Alexion is a biopharmaceutical company dedicated to the development of new drugs for rare diseases. recently, the company announced that the European Commission (EC) has appro
-
Cell interpretation! Identify new antigen targets for tumors to develop new anti-cancer immunotherapy!
Time of Update: 2020-11-27
Nov 23, 2020 // -- Cancer neoantigens, a cancer neoantigens that target tumor-specific soy cell mutations, may be a very attractive and challenging strategy for specifically removing tumor cells throu
-
Science Advances: JAK inhibitor Baricitinib reduces death rate in patients with new crown COVID-19 by 71%
Time of Update: 2020-11-26
A study by Karolinska Institutet in Sweden found that the rheumatoid arthritis drug JAK inhibitor Baricitinib blocked virus invasion and reduced mortality in patients with moderate to severe COVID-19.
-
BTK inhibitor Rilzabrutinib treats immunoplate plateroid reduction: awarded FDA fast track designation
Time of Update: 2020-11-26
The U.S. Food and Drug Administration (FDA) awarded fast-track designation (FTD) to Sanofi's oral Bruton tyrosine kinase (BTK) inhibitor, Rilzabrutinib, which is likely to be the first BTK inhibitor to treat immunoplate plateroid reduction (ITP).
photo source: About Rilzabrutinib Rilzabrutinib is an oral reversible BTK inhibitor that is being studied for the treatment of immuno-mediated diseases.
-
Cell's paper details the mechanisms of inflammatory cell death, tissue damage, and death in SARS-CoV-2 infection and cytokine shock syndrome, TNF-α and IFN-γ
Time of Update: 2020-11-25
the authors identified drug candidates after finding that the excessive inflammatory immune response associated with COVID-19 led to tissue damage and multi-organ failure in mice by triggering the death of inflammatory cells.
-
Target C3 nephropathy (C3G) the underlying cause! Novaral's powerful selective factor B inhibitor iptacopan significantly reduces proteinuria levels!
Time of Update: 2020-11-11
() Original origin: Novartis presents offers interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G)
-
New drug for plaque-type psoriasis! Leo Pharmaceuticals Enstilar foam agent long-term treatment has significant efficacy and good safety!
Time of Update: 2020-11-11
Oct 26, 2020 // -- LEO Pharma recently announced that the U.S. Food and Drug Administration (FDA) has approved enstilar (calcistol/dipropanate) U.S. Prescription Information (USPI) update to include data from the PSO-LONG clinical trial, which evaluated the treatment of adult plaque psoriasis 2 times a week for long-term use (52 weeks).
-
Recent advances in liver cancer research are at a glance
Time of Update: 2020-11-10
October 27, 2020 // -- This issue brings you the latest research advances in the field of liver cancer, and I hope readers and friends will enjoy it. 1. JCRC: A new study reveals that a team of scien
-
PNAS: Interpretation! Scientists are expected to use a new polysaccharose labeling strategy to uncover immune activation mechanisms in the liver!
Time of Update: 2020-11-10
A recent study published in the international journal Proceedings of the National Academy of Sciences entitled "Mapping glycan-mediated galectin-3 interactions by live cellity proximity labeling", scientists from institutions such as the Scripps Institute have developed a new strategy to capture the interaction between polysaccharin molecules and special protein activators in human liver cells, allowing researchers to apply new technologies to understand the mechanisms of immune activation of liver disease.
